Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 17/20 | 0.70 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391289 | 0.93 | CMA1 (0.69) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL3391294 | 0.93 | CMA1 (0.69) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL7908643 | 0.93 | CMA1 (0.71) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL999504 | 0.92 | CMA1 (0.73) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL1000031 | 0.91 | CMA1 (0.56) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL7900120 | 0.91 | CMA1 (0.61) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL998292 | 0.90 | CMA1 (0.70) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL998914 | 0.89 | CMA1 (0.55) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL997642 | 0.89 | CMA1 (0.69) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL3127647 | 0.89 | CMA1 (0.69) | CMA1PRSS1PRSS2CTSGPRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011500682-A | — | — | 2011-01-06 | — | — | JP | claimed |
| US-8546358-B2 | Method of treating asthma | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-01 | — | — | US | disclosed |
| US-20130131401-A1 | PROCESS FOR THE PREPARATION OF CHYMASE MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-23 | — | — | US | disclosed |
| US-20130131401-A1 | PROCESS FOR THE PREPARATION OF CHYMASE MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-23 | — | — | US | disclosed |
| US-8378122-B2 | Process for the preparation of chymase modulators | JANSSEN PHARMACEUTICA NV. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-8378122-B2 | Process for the preparation of chymase modulators | JANSSEN PHARMACEUTICA NV. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-20120309986-A1 | PROCESS FOR THE PREPARATION OF CHYMASE MODULATORS | ANZALONE LUIGI (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309986-A1 | PROCESS FOR THE PREPARATION OF CHYMASE MODULATORS | ANZALONE LUIGI (US) | 2012-12-06 | — | — | US | disclosed |
| US-8263785-B2 | Process for the preparation of chymase modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-09-11 | — | — | US | disclosed |
| US-8263785-B2 | Process for the preparation of chymase modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-09-11 | — | — | US | disclosed |
| US-20100048513-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2010-02-25 | — | — | US | disclosed |
| US-20100048513-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2010-02-25 | — | — | US | disclosed |
| US-20090036409-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2009-02-05 | — | — | US | disclosed |
| US-20090036409-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2009-02-05 | — | — | US | disclosed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | disclosed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | disclosed |
| WO-2008051489-A2 | SALT FORMS OF SUBSTITUTED BENZOTHIENYL COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-05-02 | — | — | WO | disclosed |
| US-20080097110-A1 | Salt forms of substituted benzothienyl compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-24 | — | — | US | disclosed |
| US-20080097110-A1 | Salt forms of substituted benzothienyl compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-24 | — | — | US | disclosed |
| WO-2005073214-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048513-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | CMA1 1/4885PRSS1 5/4885PRSS2 20/4885 |
| US-20090036409-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | CMA1 1/4885PRSS1 5/4885PRSS2 20/4885 |
| US-20130131401-A1 | PROCESS FOR THE PREPARATION OF CHYMASE MODULATORS | CMA1, SERPINB1, CPA3 | CMA1 1/4885PRSS1 4/4885PRSS2 22/4885 |
| US-20080097110-A1 | Salt forms of substituted benzothienyl compounds | SLC10A1, REN, SLC10A6 | CMA1 1104/4885PRSS1 1753/4885PRSS2 2527/4885 |
| US-20120309986-A1 | PROCESS FOR THE PREPARATION OF CHYMASE MODULATORS | CMA1, SERPINB1, CPA3 | CMA1 1/4885PRSS1 4/4885PRSS2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.